Knott Tanya, Creeden James, Horbach Benjamin, Rauch-Zumbrägel Maximiliane, Vat Lidewij, Harnik Helena, Maravic Zorana
Sarah Jennifer Knott Foundation Dublin Ireland.
From Testing to Targeted Treatments (FT3) Board Member, The Synergist Brussels Belgium.
Health Sci Rep. 2023 Aug 17;6(8):e1428. doi: 10.1002/hsr2.1428. eCollection 2023 Aug.
To sustainably address challenges in implementing precision medicine (PM), coordinated efforts of different stakeholders are required. Understanding their expectations represents a first key step toward aligning on future actions and strategies. Here, we aimed to explore the expectations of different stakeholders from themselves and each other regarding PM.
This collaborative qualitative study was initiated by the global multistakeholder consortium From Testing to Targeted Treatments (FT3). Structured interviews were conducted with participants from five stakeholder groups: patients/patient advocates, healthcare providers (HCPs), researchers, policymakers/regulators/payers and industry representatives. A broad reach across geography, roles, experiences, and disease areas was sought. Results were analyzed by grounded theory methodology.
All stakeholders stated that optimal implementation of PM can only be achieved through collaboration; industry representatives were the biggest promoters of collaboration. Stakeholders agreed that PM should be implemented focusing on the patient's best interest; HCPs were seen as important gatekeepers for PM by interacting directly with patients, and policymakers/payers were perceived as the most important drivers of access to PM. Areas of misalignment included the role of industry in clinical trial design and in access to PM (perceived as important by patients, HCPs and policymakers but not by industry representatives), and the stakeholders responsible for elaborating guidelines on PM use (patients indicated policymakers, while researchers indicated themselves). Priorities for optimal PM implementation and suggested actions included the need for enhancing high-level policy focus, improving genomic literacy, optimizing the health technology assessment for PM, advocating for equitable access, promoting collaboration between industry and other stakeholder groups and development of reliable research standards.
Stakeholder expectations revealed in this study suggested that no stakeholder group can drive change on its own; a global, multistakeholder collaborative approach that brings together current programs and best practices to support universal access to PM is needed.
为了可持续地应对实施精准医学(PM)过程中遇到的挑战,需要不同利益相关者的协同努力。了解他们的期望是朝着未来行动和战略达成一致迈出的关键第一步。在此,我们旨在探讨不同利益相关者对自身以及彼此在精准医学方面的期望。
这项合作性定性研究由全球多利益相关者联盟“从检测到靶向治疗”(FT3)发起。对来自五个利益相关者群体的参与者进行了结构化访谈:患者/患者倡导者、医疗服务提供者(HCPs)、研究人员、政策制定者/监管者/支付方以及行业代表。力求在地域、角色、经验和疾病领域实现广泛覆盖。采用扎根理论方法对结果进行分析。
所有利益相关者均表示,只有通过合作才能实现精准医学的最佳实施;行业代表是合作的最大推动者。利益相关者一致认为,精准医学的实施应以患者的最大利益为重点;医疗服务提供者通过直接与患者互动被视为精准医学的重要把关人,而政策制定者/支付方被视为获得精准医学的最重要驱动因素。存在分歧的领域包括行业在临床试验设计和获得精准医学方面的作用(患者、医疗服务提供者和政策制定者认为很重要,但行业代表不这么认为),以及负责制定精准医学使用指南的利益相关者(患者认为是政策制定者,而研究人员认为是他们自己)。精准医学最佳实施的优先事项和建议行动包括需要加强高层政策关注、提高基因组素养、优化精准医学的卫生技术评估、倡导公平获取、促进行业与其他利益相关者群体之间的合作以及制定可靠的研究标准。
本研究中揭示的利益相关者期望表明,没有一个利益相关者群体能够独自推动变革;需要一种全球多利益相关者协作方法,将当前的项目和最佳实践结合起来,以支持普遍获得精准医学。